KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Asset Writedowns and Impairment: 2009-2024

Historic Asset Writedowns and Impairment for Idexx Laboratories (IDXX) over the last 6 years, with Mar 2024 value amounting to $250,000.

  • Idexx Laboratories' Asset Writedowns and Impairment was N/A to $250,000 in Q1 2024 from the same period last year, while for Mar 2024 it was $3.6 million, marking a year-over-year change of. This contributed to the annual value of $250,000 for FY2024, which is 83.15% down from last year.
  • Per Idexx Laboratories' latest filing, its Asset Writedowns and Impairment stood at $250,000 for Q1 2024, which was down 83.15% from $1.5 million recorded in Q4 2023.
  • Idexx Laboratories' 5-year Asset Writedowns and Impairment high stood at $2.0 million for Q3 2020, and its period low was $250,000 during Q1 2024.
  • Over the past 2 years, Idexx Laboratories' median Asset Writedowns and Impairment value was $867,000 (recorded in 2023), while the average stood at $867,000.
  • Data for Idexx Laboratories' Asset Writedowns and Impairment shows a maximum YoY plummeted of 47.52% (in 2020) over the last 5 years.
  • Idexx Laboratories' Asset Writedowns and Impairment (Quarterly) stood at $508,000 in 2020, then slumped by 32.11% to $1.4 million in 2021, then reached $1.5 million in 2023, then reached $250,000 in 2024.
  • Its last three reported values are $250,000 in Q1 2024, $1.5 million for Q4 2023, and $1.4 million during Q3 2021.